Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$15.15 USD
-1.11 (-6.83%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $15.04 -0.11 (-0.73%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
ASMB 15.15 -1.11(-6.83%)
Will ASMB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ASMB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ASMB
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
Is Sensus Healthcare (SRTS) Stock Outpacing Its Medical Peers This Year?
ASMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
TEVA Shares Rise on Broad Support for Opioids Settlement
Other News for ASMB
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
FedEx, PepsiCo downgraded: Wall Street's top analyst calls
Assembly Biosciences just upgraded at Jefferies, here's why
Eleven option delistings on August 19th
H.C. Wainwright Remains a Hold on Assembly Biosciences (ASMB)